- Report
- July 2026
- 150 Pages
North America
From €4324EUR$4,750USD£3,721GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1138EUR$1,250USD£979GBP
- Report
- August 2026
- 70 Pages
India
From €4324EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
Egypt
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 150 Pages
Global
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Japan
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Italy
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4324EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4324EUR$4,750USD£3,721GBP
- Report
- May 2026
- 200 Pages
Canada
From €2539EUR$2,789USD£2,185GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2539EUR$2,789USD£2,185GBP
- Report
- June 2025
- 400 Pages
Global
From €4505EUR$4,949USD£3,877GBP
- Report
- August 2024
- 150 Pages
Global
From €2539EUR$2,789USD£2,185GBP
- Report
- May 2023
- 147 Pages
Global
From €4505EUR$4,949USD£3,877GBP
- Report
- August 2026
- 70 Pages
Mexico
From €4324EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
Malaysia
From €4324EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
Vietnam
From €4324EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
Thailand
From €4324EUR$4,750USD£3,721GBP
- Report
- August 2026
- 120 Pages
Mexico
From €4324EUR$4,750USD£3,721GBP

Alpha Glucosidase Inhibitors are a class of drugs used to treat Endocrine and Metabolic Disorders. These drugs work by inhibiting the enzyme alpha-glucosidase, which is responsible for breaking down carbohydrates in the small intestine. This helps to reduce the amount of glucose absorbed into the bloodstream, which can help to control blood sugar levels. Alpha Glucosidase Inhibitors are commonly used to treat type 2 diabetes, as well as other conditions such as polycystic ovary syndrome and gestational diabetes.
Alpha Glucosidase Inhibitors are available in both oral and injectable forms. Common side effects of these drugs include abdominal pain, nausea, and diarrhea. Long-term use of these drugs can also lead to an increased risk of hypoglycemia.
Some companies that produce Alpha Glucosidase Inhibitors include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more